Security Snapshot

Ultragenyx Pharmaceutical Inc. - Common Stock, $0.001 par value (RARE) Institutional Ownership

CUSIP: 90400D108

13F Institutional Holders and Ownership History from Q1 2014 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

188

Shares (Excl. Options)

76.47MFull value: 76,468,612 · shares · 30 Sep 2026

Price

$15.03

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
+1,783,430
Value change
-$206,938,047
Number of holders
188
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
98,967,656
SEC-reported price per share
$16.08
Insider filing price
$16.08
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • RARE - Ultragenyx Pharmaceutical Inc. - Common Stock, $0.001 par value is tracked under CUSIP 90400D108.
  • 188 institutions reported positions in Q3 2026.
  • 10 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 312 to 188 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $3.55BFull value: $3,551,507,252 · USD · 30 Jun 2026
    to
    $1.15BFull value: $1,149,621,274 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 188 institutions filings for Q3 2026.

Open SEC evidence

Security key

90400D108

13F reference period

Q3 2026

13F holders

188

13D/G owners

10

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
10
Security
RARE
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
VANGUARD PORTFOLIO MANAGEMENT LLC 8.6% +24% $127,473,428 +$24,466,420 8,481,266 +24% Vanguard Portfolio Management 30 Sep 2026
BlackRock, Inc. 8.3% +64% $271,840,812 +$110,869,926 8,141,384 +69% BlackRock, Inc. 30 Jun 2026
RTW INVESTMENTS, LP 7.9% $260,338,324 7,796,895 RTW Investments, LP 30 Jun 2026
STATE STREET CORP 7.6% +22% $113,297,312 +$20,731,059 7,538,078 +22% STATE STREET CORPORATION 30 Sep 2026
Madison Avenue Partners, LP 6.4% $94,806,204 6,307,798 Madison Avenue International LP 13 Oct 2026
VANGUARD CAPITAL MANAGEMENT LLC 5.1% $168,900,610 5,058,419 Vanguard Capital Management 30 Jun 2026
SANDS CAPITAL MANAGEMENT, LLC 4.7% $163,238,154 4,298,003 SANDS CAPITAL MANAGEMENT, LLC 31 Dec 2024
FMR LLC 3.5% -60% $77,001,475 -$106,192,081 3,347,890 -58% FMR LLC 31 Dec 2025
WELLINGTON MANAGEMENT GROUP LLP 2.7% $93,337,483 2,457,543 Wellington Management Group LLP 31 Dec 2024
AQR CAPITAL MANAGEMENT LLC 0.64% -86% $9,519,897 -$89,089,062 633,393 -90% AQR Capital Management, LLC 30 Sep 2026
As of 30 Sep 2026, 188 institutional investors reported holding
76.47MFull value: 76,468,612 · shares · 30 Sep 2026
shares of Ultragenyx Pharmaceutical Inc. - Common Stock, $0.001 par value (RARE). This represents 77% of the company’s total
98.97MFull value: 98,967,656 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 25 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
56%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
RTW INVESTMENTS, LP 8.6% 8,529,394 1.3% $128,196,792
VANGUARD PORTFOLIO MANAGEMENT LLC 8.5% 8,419,105 0.01% $126,539,148
STATE STREET CORP 7.6% 7,538,078 0% $113,297,312
VANGUARD CAPITAL MANAGEMENT LLC 4.3% 4,299,168 0% $64,616,495
TWO SIGMA INVESTMENTS, LP 3.2% 3,130,527 0.03% $47,051,821
Nantahala Capital Management, LLC 2.4% 2,339,293 2% $35,159,574
GEODE CAPITAL MANAGEMENT, LLC 2.2% 2,174,052 0% $32,683,698
GOLDMAN SACHS GROUP INC 1.9% 1,915,608 0% $28,791,591
Sofinnova Investments, Inc. 1.8% 1,753,703 1.3% $26,358,156
Madison Avenue Partners, LP 1.7% 1,705,351 1% $25,631,426
Qube Research & Technologies Ltd 1.4% 1,345,150 0.02% $20,217,605
Jefferies Financial Group Inc. 1.4% 1,339,814 0.27% $20,137,404
Krensavage Asset Management, LLC 1.2% 1,140,867 6.5% $17,147,000
Trexquant Investment LP 1.1% 1,084,251 0.1% $16,296,293
ALGERT GLOBAL LLC 1% 1,008,185 0.18% $15,153,021
Rock Springs Capital Management LP 0.93% 925,089 0.75% $13,904,088
VOLORIDGE INVESTMENT MANAGEMENT, LLC 0.93% 923,094 0.06% $13,874,103
Point72 Asset Management, L.P. 0.85% 844,410 0.02% $12,691,482
PANAGORA ASSET MANAGEMENT INC 0.78% 776,473 0.04% $11,670,389
RAYMOND JAMES FINANCIAL INC 0.77% 766,532 0% $11,520,976
Saturn V Capital Management LP 0.77% 758,771 1.7% $11,404,328
SUSQUEHANNA INTERNATIONAL GROUP, LLP 0.75% 739,697 0.01% $11,117,646
ExodusPoint Capital Management, LP 0.73% 726,002 0.08% $10,911,810
WELLINGTON MANAGEMENT GROUP LLP 0.73% 724,265 0% $10,885,702
Palo Alto Investors LP 0.72% 710,029 1.6% $10,671,736

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
51
Headline period
Q3 2026
Rows shown
1-25 of 51
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 76,468,612 $1,149,621,274 -$206,938,047 $15.03 188
2026 Q2 106,698,620 $3,551,507,252 +$344,179,807 $33.39 312
2026 Q1 98,238,220 $2,056,267,839 +$65,699,610 $20.95 297
2025 Q4 93,873,177 $2,157,035,170 -$88,987,931 $23.00 286
2025 Q3 95,480,928 $2,872,333,685 -$30,390,841 $30.08 301
2025 Q2 94,131,376 $3,423,160,510 +$191,188,547 $36.36 307
2025 Q1 88,841,861 $3,218,915,813 +$30,616,617 $36.21 297
2024 Q4 87,497,812 $3,681,153,433 +$1,949,206 $42.07 309
2024 Q3 86,896,233 $4,824,969,188 -$72,319,917 $55.55 299
2024 Q2 88,212,580 $3,625,598,894 +$337,028,289 $41.10 273
2024 Q1 79,925,459 $3,729,060,008 -$19,184,689 $46.69 268
2023 Q4 80,397,353 $3,844,802,509 +$498,492,380 $47.82 236
2023 Q3 70,612,041 $2,517,056,820 +$10,459,486 $35.65 219
2023 Q2 69,514,116 $3,206,303,623 +$38,331,356 $46.13 239
2023 Q1 68,735,803 $2,755,924,776 +$28,159,264 $40.10 227
2022 Q4 68,068,127 $3,153,029,340 +$13,205,113 $46.33 225
2022 Q3 67,920,512 $2,812,302,784 -$149,070,496 $41.41 223
2022 Q2 67,540,585 $4,030,154,883 +$24,063,212 $59.66 210
2022 Q1 67,087,441 $4,870,684,649 -$37,258,962 $72.62 227
2021 Q4 67,646,883 $5,688,385,130 +$80,515,709 $84.09 224
2021 Q3 66,666,465 $6,012,124,489 +$97,920,619 $90.19 217
2021 Q2 65,481,898 $6,240,143,536 -$246,149,121 $95.35 235
2021 Q1 67,877,270 $7,730,039,829 +$45,641,218 $113.86 244
2020 Q4 67,658,657 $9,366,525,048 +$640,902,584 $138.43 247
2020 Q3 63,092,193 $5,187,430,003 -$8,503,385 $82.19 199
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .